|
**Overview**: **OncoPro Pancancer Panel****Introduction**: The OncoPro Pancancer Panel Test is a diagnostic tool designed to screen for TP53, KRAS, and BRAF mutations via liquid biopsy in plasma samples, facilitating the diagnosis of cancer. Associated with various malignancies including colorectal or melanoma, these oncologic conditions present with swelling, pain, and severe complications like metastasis if untreated, particularly in individuals with genetic predisposition or chronic inflammation. Per the 2023 National Comprehensive Cancer Network guidelines, the test employs molecular pathology with PCR technology, delivering detailed genetic identification over 5-7 days with high sensitivity and specificity, making it a valuable tool for definitive diagnosis in molecular pathology settings. This diagnostic falls under cancer screening and targets individuals with systemic or dermatologic symptoms, addressing the challenge of accurate mutation classification to guide targeted therapy. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating treatment, and reducing complications. Its plasma-based approach ensures non-invasive detection.**Other Names**: Pancancer Panel Test.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2010s by various molecular labs, this test advanced cancer diagnostics by standardizing multi-gene liquid biopsy analysis.**Purpose**: The test screens for TP53 mutations, KRAS mutations, and BRAF mutations to guide cancer diagnosis, assess oncologic status, and inform treatment and prevention strategies.**Test Parameters**: Presence of TP53 mutations, KRAS mutations, and BRAF mutations, detected with high specificity to indicate cancerous activity, typically observable in plasma at altered genetic patterns during active disease, with mutation prevalence and type assessed to determine severity and distribution, providing a comprehensive profile of tumor damage that correlates with clinical presentation and guides therapeutic decisions, ensuring a detailed evaluation of affected genetic components.**Pretest Condition**: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report swelling, pain, or recent cancer symptoms.**Specimen**: Plasma 2-4 mL, collected using EDTA tubes, transported within 8 hours to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling in a cool environment to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not recommended, as freezing may degrade DNA, increasing the risk of false negatives and compromising diagnostic accuracy.**Medical History**: Patients should provide details on swelling, pain, prior cancer, or family history of oncologic disease, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated cancer including metastasis, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves plasma processing, DNA extraction, PCR amplification, and analysis by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 5-7 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond 8 hours, improper storage conditions, cross-contamination with other samples, or recent therapy can affect results. Correlation with imaging or clinical evaluation is recommended to confirm findings.**Clinical Significance**: A positive result indicates possible cancer, necessitating further investigation like imaging or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during early stages.**Specialist Consultation**: Oncologists should be consulted for case management, treatment planning, and coordination with cancer programs.**Additional Supporting Tests**: CT scan, biopsy review, or CEA testing for confirmation.**Test Limitations**: The test may produce false negatives in low tumor burden or false positives in contamination, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: NCCN Guidelines 2023, Journal of Molecular Diagnostics 2024, Molecular Pathology 2025. |
